Baidu
map

JAMA Dermatol:冷水泼来了!连皮肤病的远程医疗不靠谱!

2016-05-18 徐青/编译 健康界

编者按:国内移动医疗一直有一个争议:能不能直接做医患间的远程诊疗?业内大多数人认为,这种模式应该从皮肤病、心理咨询等逐渐放开。但日前JAMA的一项研究表明,对皮肤病的远程问诊并不那么靠谱。 近几年,直面患者(Direct to Consumer,DTC)的远程医疗呈爆炸式发展,甚至很多保险公司也将其列在保险计划范围内,作为方便、低成本医疗的方式来推广。据美国远程医疗协会(American T

MedSci小编:

移动医疗风起云涌,尤其是医患远程问诊,一直争议不断。但是,大家至少有共识,在皮肤病这个领域应该是靠谱的,尤其是随着手机的普及,拍个照片看看是相似的。然而,最新的JAMA子刊一篇研究让人跌破眼球:皮肤病的远程诊疗也不靠谱!各位看观仔细往下看:

近几年,直面患者(Direct to Consumer,DTC)的远程医疗呈爆炸式发展,甚至很多保险公司也将其列在保险计划范围内,作为方便、低成本医疗的方式来推广。据美国远程医疗协会(American Telemedicine Association)统计,预计2016年会有超过100万次虚拟问诊。在虚拟问诊飞速发展的同时,也有人开始担心这种医疗方式会破坏医患关系、拉低医疗质量并侵蚀医疗系统。

此前研究发现,皮肤病学作为远程医疗技术的最早使用者,对某些疾病的诊断准确性达到了和面对面诊断相似的效果,还降低了费用。但是这种远程医疗的模式,是患者的一位医生将其病史和图片发送给皮肤病学家,请他们给出建议。而现在的模式是,患者通过远程医疗网站直接和医生建立联系,很多情况下患者都没有选择医生的权力。

为了检验这种远程医疗的有效性,美国JAMA皮肤病学杂志(JAMA Dermatology)在美国加州进行了一项研究。研究人员设定了6个虚拟患者,根据患者年龄、性别设计了不同的疾病,并准备了相关图片和病史等细节以供在线咨询。


从2016年2月4日到2016年3月11日,研究人员从16个DTC远程医疗网站得到了62个回复。但是没有任何一次咨询质疑咨询者的身份或提供的资料,其中42次咨询中,患者并没有选择医生的权力而是系统直接给分配医生。其中只有16次提供了医生的执业信息,很多国际医生并没有在加州行医的资质。在62次咨询中,只有14位医生询问了患者家庭医生的名字,只有6位要求家庭医生寄患者病历。在62次远程问诊中,48位医生给出了诊断,其中31位给患者开了药,但是只有10位医生给了患者关于副作用或怀孕风险等警告。

报告称,对于可以从照片直接看出的疾病,远程诊断基本上正确,7位医生都对瘀血性皮炎(血液循环不良造成的炎症)给出了正确诊断和恰当治疗方案。

但是对于需要更多病史信息才能做出诊断的疾病,这些医生基本上都没有进一步询问相关信息,诊断结果也不够准确。

例如,14个遇到细节性黑素瘤的医生中只有11位告诉患者需要亲自看医生,但是其中有三个告诉患者这是良性的。12位接受患有炎性粉刺的年轻女患者咨询的医生,没有一个人询问患者是否出现月经不调或有可见面部毛发,这12位医生也都没有发现患者是多囊卵巢综合征,这是一种需要激素治疗的复杂疾病。同样,对于二期梅毒的小伙子,也没有一位医生询问他身上突然出现的皮肤斑块和最近的发烧。甚至8位医生中有7位同意患者的推测——牛皮癣,而完全没有发现这种严重并有可能传染的性病。

抛开错误的诊断结果,很多医生给出的治疗也不符合规定。其中一位女性患者的资料显示身上的疱疹通过湿疹在蔓延,可能危及生命,但是9位医生中的7位都出现了误诊。有两个医生还开了口服强的松,这种药只会加剧病情。

报告指出,我们无法知道真正面对面的医患交流是否会给出更好的结果,但是该报告的首席作者、加州大学皮肤病学者Jack Resneck称,“在这种远程咨询中,医患之间的意见交流消失了,一些基本的问题医生都没有询问。”

报告指出,远程医疗确实很有发展潜力,也有很多例子证明,远程医疗系统可以提供优质医疗服务。但是这份报告开始让人质疑远程医疗对于皮肤病的诊治,因此目前针对远程医疗的一系列医保计划也许并不成熟。报告认为DTC远程医疗可以更有效地利用,但是至少需要一些质量认证。美国远程医疗协会CEO乔纳森·林考斯(Jonathan Linkous)同样认为,对于新兴的虚拟问诊有必要进行质量监控。

为此,2015年美国远程医疗协会开始了一项认证项目来提高远程医疗水平,虽然有将近500家机构申请,但是到目前为止只有7家远程医疗公司通过认证。

对于远程医疗公司,报告最后也给出了几点建议:

1. 展示出医生的执照、文凭和所在地,并且给患者选择医生的权力。

2. 对于患者要获取其身份证明,并且在首次问诊中和患者通过视频交流。

3. 收集患者病史的相关资料,包括所咨询疾病的病史、其他机构的诊断、用药和药物过敏情况。

4. 精确的诊断基于双方的互动,应该训练医生主动询问,全面了解患者相关病史。

5. 根据已有的循证指示给出诊断和治疗方案。

6. 开药时应该告知患者存在的危险、副作用、妊娠注意事项等。

7. 和患者现有的医疗团队联系,并给他们发送医疗记录,除非患者反对。

8. 和患者所在地各科室的医生保持联系,以免患者突发紧急情况时被送到急诊中心或无人照料。

9. 建立质量鉴定项目,定期对临床诊治、疗效、后期跟踪等进行监测。

林考斯博士提醒:“用户也应该小心,要知道自己咨询的是谁,询问对方的授权资质。自己也要主动,如果还有需要医生知道的信息,一定要说出来。”

原始出处:

Jack S. Resneck Jr; Michael Abrouk2; Meredith Steuer, MMS2; Andrew Tam2; Adam Yen2; Ivy Lee, MD3; Carrie L. Kovarik, MD4; Karen E. Edison.Direct-to-Consumer Telemedicine Websites Treating Skin Disease.JAMA Dermatol. Published online May 15, 2016. doi:10.1001/jamadermatol.2016.1774 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 李继凯

    理想与现实的差距

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 1dd8c52fm63(暂无匿称)

    了解一下!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 milkshark

    实践证明

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 milkshark

    的确不行

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-18 文医生

    希望能够成真啊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1756621, encodeId=fd811e56621c3, content=<a href='/topic/show?id=ba8e99e857c' target=_blank style='color:#2F92EE;'>#靠谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99785, encryptionId=ba8e99e857c, topicName=靠谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=199a37204836, createdName=ms117281293605716, createdTime=Tue Apr 25 11:25:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826078, encodeId=c57318260e8fe, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 14 20:25:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86594, encodeId=434586594b7, content=理想与现实的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86538, encodeId=893b8653838, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:31:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86497, encodeId=07458649e55, content=实践证明, beContent=null, objectType=article, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:07:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86496, encodeId=37a28649670, content=的确不行, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 00:06:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86306, encodeId=fccd86306ea, content=希望能够成真啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed May 18 21:08:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86287, encodeId=5e818628ed0, content=远程医疗任重而道远, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed May 18 19:23:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-18 lovetcm

    远程医疗任重而道远

    0

相关资讯

何种远程问诊最有市场前景?

随着价值医疗的推动,美国的远程问诊获得了爆发式的增长。但是,远程问诊的核心市场需求到底来自哪里,主要解决了哪些问题,市场对此仍具有很大的模糊性。不过,根据美国兰德公司的最新调查报告来判断,不落地的远程问诊局限性相当大,未来的市场发展可能不会有原先想象的那么大。 这组调查的样本来自1725个使用Teladoc的病人和64099个在线下的病人对比。根据数据分析,使用远程问诊的主要是51岁以下,没

8个发展阶段绘制目前清晰的远程医疗图景

安永会计师事务所(Ernst & Young,以下简称“安永”)近日在“HIMSS 15”大会上发布了“远程医疗普及模式”,列出了远程医疗普及的8个阶段,希望能为医院系统开辟出一条可遵循的发展路线。 安永医疗保健咨询部门负责人比尔·菲拉(Bill Fera)称:“我们需要了解人们现在处于哪个位置,但目前还没有相应的标准。因此,我们想创建一个标准的模式。” 安永在创建这些

JAMA Oncol:美国人玩转肿瘤远程医疗—获益和存在的问题

Naveen Krishna和同事在11月JAMA Oncology上发表专家观点,远程医疗可以减轻面对面协商时患者的焦虑情绪,可以以一个有同情心的和以病人为中心的方式及时传递坏消息。

康美药业网络医院资质获批,远程医疗贼热闹啊

3月13日,康美药业远程医疗服务资质获广东卫计委批准。根据国家卫计委《关于推进医疗机构远程医疗服务的意见》的文件精神,康美药业将通过"康美信息化医疗服务平台"作为技术支撑,以康美医院为主体对象和复制样本,实现医疗信息化。2013年6月,康美宣布投资建设的普宁市康美医院获批。康美药业网络医院要玩啥? (一)患者个人远程咨询系统 网络医院将提供web平台、手机APP等终端,通过终端上集

国内远程移动医疗系统在沪上线

在“互联网+”时代,如何让市民享受更便捷的健康医疗服务?5月30日,一场围绕“分级诊疗模式创新”的智慧健康论坛传出消息,国内首个远程移动医疗系统已在浦东南片区域正式上线,形成医医、医患智慧健康工程新模式。“在全科医师处就诊,可以得到专科医师的指导,及时调整治疗方案。”浦东惠南镇居民马阿婆,切实享受到了“智慧健康”带来的便利。虽然惠南社区卫生服务中心与区域内综合性医院相隔不远,但不用去大医院抢号排队

IBM沃森大力拓展医疗领域,6个新合作项目亮相

自上个月宣布推出“沃森健康部门”(Watson Health)以来,IBM一直忙个不停,陆续宣布了一系列关于其认知计算软件(沃森)在医疗保健市场的合作和部署项目。   其中大部分项目是在IBM近期于纽约召开的“沃森世界”研讨会(World of Watson)上宣布的,其中包括以下6项合作:     1. IBM沃森与梅奥诊所(Mayo Clinic

Baidu
map
Baidu
map
Baidu
map